Skip to main content
Home
  • Australia
  • Austria
  • Belgium
  • Brazil
  • Chile
  • China
  • Colombia
  • France
  • Germany
  • India
  • Italy
  • Japan
  • Korea
  • Mexico
  • Netherlands
  • South Africa
  • Spain
  • Switzerland
  • Taiwan
  • United Kingdom
  • USA
  • Contact
  • English
  • French
GBT €10.36
  • Our Group
    • Guerbet in a nutshell
    • Our Corporate Responsibilities
    • Corporate Governance
    • Intrasense and Guerbet
      • Intrasense, a Guerbet Group subsidiary: Innovating in AI together
    • Careers
  • Products & Solutions
    MRI
    • Home of MRI Innovations
    • Artirem®
    • Dotarem®
    • Elucirem™ (Gadopiclenol)
    • Injectors, Accessories & Consumables
    • MRI Accessories
    • Consumables for Diagnostic Imaging
    • OptiStar® Elite
    • Ready-Box
    • Service & Support
    • OptiProtect™ 3S
    Diagnostic Imaging Interconnected Solutions…

    UNIK: Diagnostic Imaging Interconnected Solutions

    Explore our Solutions
    CT
    • Home of MRI Innovations
    • Conray® / Cysto-Conray®
    • Micropaque® / Microtrast®
    • Optiray®
    • Telebrix® Gastro
    • Xenetix® / ScanBag® by Xenetix®
    • Injectors, Accessories & Consumables
    • Consumables for Diagnostic Imaging
    • OptiBolus®
    • OptiOne™
    • OptiVantage™ Multi-use
    • OptiVantage™ Single-use
    • Ready-Box
    • Service & Support
    • OptiProtect™ 3S
    Diagnostic Imaging Interconnected Solutions…

    UNIK: Diagnostic Imaging Interconnected Solutions

    Explore our Solutions
    Cath Lab
    • Home of MRI Innovations
    • Optiray®
    • Xenetix® / ScanBag® by Xenetix®
    • Injectors, Accessories & Consumables
    • Consumables for Diagnostic Imaging
    • Illumena® Néo
    • Ready-Box
    • Service & Support
    • OptiProtect™ 3S
    Diagnostic Imaging Interconnected Solutions…

    UNIK: Diagnostic Imaging Interconnected Solutions

    Explore our Solutions
    Interventional Radiology
    • Pharmaceutical Drugs
    • Lipiodol® Ultra Fluid
    • Medical Devices
    • Qitexio®
    Solutions d’imagerie interventionnelle

    Interventional Imaging Solutions

    Explore our Solutions
    Women's Health
    • Pharmaceutical Drugs
    • Patent Blue V
    • Lipiodol® Ultra Fluid
    Fertility and women's health

    Women’s Health

    Explore our Solutions
  • Investors
    • Key Figures
    • Stock Performance
    • Financial Policy
    • Presentations, Reports & Regulated information
    • Agenda
    • General Meetings
  • Media
  • Educational Resources
  • Patient Resources
    • Blue November
    • Liver Cancer Awareness Month
    • Osteoarthritis
  • 100 years
    • Celebrating 100 years
    • Guerbet Saga
  • Careers

Media

Welcome to Guerbet Media section for journalists. The press releases are intended for their professional use. Find our latest press releases and our media resources.

Media…
  1. Homepage
  2. Media

Our Latest Press Releases

Changes to the Composition of Guerbet’s Board of Directors

Read the article

Guerbet announces an important milestone achievement in the “Vascular Embolization” indication for Lipiodol® Ultra Fluid (Iodinated ethyl esters of fatty acids of poppy seed oil)

Read the article

Q1 2026 revenue

Read the article
Where we are located

Changes to the Composition of Guerbet’s Board of Directors

Read the article

Guerbet announces an important milestone achievement in the “Vascular Embolization” indication for Lipiodol® Ultra Fluid (Iodinated ethyl esters of fatty acids of poppy seed oil)

Read the article

Q1 2026 revenue

Read the article

2025 full-year results

Read the article

Change in Guerbet’s Board of Directors

Read the article
First-half 2021 revenue

2025 revenue

Read the article

Karim Boussebaa Appointed Chief Executive Officer of Guerbet

Read the article

New indication in children from birth for Guerbet’s half-dose GBCA, Elucirem™ (Gadopiclenol) approved by European Commission

Read the article
Where we are located

Guerbet announces the appointment of Mr. François Convenant as Senior Vice President of Interventional Radiology and his entry into the Executive Committee

Read the article
  • Current page1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • ›
Image
Logo Guerbet
  • Legal Information
  • Cookie Policy
  • Data Protection Policy
  • Patents
  • Contact
Copyright © Guerbet
2026
  • LinkedIn
  • Twitter
  • Instagram
  • YouTube